Angiotensin II-mediated microvascular thrombosis

Hypertension

Volumn 56, Issue 6, 2010, Pages 1089-1095

  Senchenkova, Elena Y ^a   Russell, Janice ^a   Almeida Paula, Lidiana D ^a   Harding, Joseph W ^b   Granger, D Neil ^a  

^a LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b WASHINGTON STATE UNIVERSITY   (United States)

Author keywords

angiotensin; bradykinin; endothelin 1; platelet aggregation; thrombosis

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN II; ANGIOTENSIN RECEPTOR; BRADYKININ; BRADYKININ B1 RECEPTOR; BRADYKININ B2 RECEPTOR; ENDOTHELIN 1; ENDOTHELIN RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERIOLE; ARTICLE; CONTROLLED STUDY; HYPERTENSION; MALE; MICROVASCULATURE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RECEPTOR INTRINSIC ACTIVITY; SIGNAL TRANSDUCTION; THROMBOCYTE AGGREGATION; THROMBOGENESIS; THROMBOSIS; VENULE;

ANGIOTENSIN II; ANGIOTENSIN RECEPTOR ANTAGONISTS; ANIMALS; HYPERTENSION; MALE; MICE; MICE, INBRED C57BL; MICROVESSELS; PLATELET AGGREGATION; RECEPTORS, ANGIOTENSIN; RECEPTORS, BRADYKININ; RECEPTORS, ENDOTHELIN; THROMBOSIS;

EID: 78650420058     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.110.158220     Document Type: Article

References (41)

1. Nadar S, Lip GY. The prothrombotic state in hypertension and the effects of antihypertensive treatment. Curr Pharm Des. 2003;9:1715-1732. (Pubitemid 36958345)
2. Prandoni P. Links between arterial and venous disease. J Intern Med. 2007;262:341-350.
3. Broeders MA, Tangelder GJ, Slaaf DW, Reneman RS, oude Egbrink MG. Hypercholesterolemia enhances thromboembolism in arterioles but not venules: complete reversal by L-arginine. Arterioscler Thromb Vasc Biol. 2002;22:680-685.
4. Brown NJ, Vaughan DE. Prothrombotic effects of angiotensin. Adv Intern Med. 2000;45:419-429.
5. Skowasch D, Viktor A, Schneider-Schmitt M, Luderitz B, Nickenig G, Bauriedel G. Differential antiplatelet effects of angiotensin converting enzyme inhibitors: comparison of ex vivo platelet aggregation in cardiovascular patients with ramipril, captopril and enalapril. Clin Res Cardiol. 2006;95:212-216.
6. Monton M, Jimenez A, Nunez A, Lopez-Blaya A, Farre J, Gomez J, Zalba LR, Sanchez de Miguel L, Casado S, Lopez-Farre A. Comparative effects of angiotensin II AT-1-type receptor antagonists in vitro on human platelet activation. J Cardiovasc Pharmacol. 2000;35:906-913.
7. Kaminska M, Mogielnicki A, Stankiewicz A, Kramkowski K, Domaniewski T, Buczko W, Chabielska E. Angiotensin II via AT1 receptor accelerates arterial thrombosis in renovascular hypertensive rats. J Physiol Pharmacol. 2005;56:571-585.
8. Jimenez AM, Monton M, Garcia R, Nunez A, Gomez J, Rico L, Garcia-Colis E, de Miguel LS, Arriero MM, Cabestrero F, Farre J, Casado S, Lopez-Farre A. Inhibition of platelet activation in stroke-prone spontaneously hypertensive rats: comparison of losartan, candesartan, and valsartan. J Cardiovasc Pharmacol. 2001;37:406-412.
9. Zhuo J, Moeller I, Jenkins T, Chai SY, Allen AM, Ohishi M, Mendelsohn FA. Mapping tissue angiotensin-converting enzyme and angiotensin AT1, AT2 and AT4 receptors. J Hypertens. 1998;16:2027-2037.
10. Alexander BT, Cockrell KL, Rinewalt AN, Herrington JN, Granger JP. Enhanced renal expression of preproendothelin mRNA during chronic angiotensin II hypertension. Am J Physiol Regul Integr Comp Physiol. 2001;280:R1388-R1392.
11. Kintsurashvili E, Duka I, Gavras I, Johns C, Farmakiotis D, Gavras H. Effects of ANG II on bradykinin receptor gene expression in cardiomyo-cytes and vascular smooth muscle cells. Am J Physiol Heart Circ Physiol. 2001;281:H1778-H1783.
12. Merkulov S, Zhang WM, Komar AA, Schmaier AH, Barnes E, Zhou Y, Lu X, Iwaki T, Castellino FJ, Luo G, McCrae KR. Deletion of murine kininogen gene 1 (mKng1) causes loss of plasma kininogen and delays thrombosis. Blood. 2008;111:1274-1281.
13. Kimura S, Tsuji H, Nishimura H, Kato H, Ukimura N, Yano S, Kunieda Y, Kawano H, Nakagawa K, Nakagawa M. Bradykinin enhances in vitro procoagulant and antifibrinolytic properties of rat vascular endothelial cells. Thromb Res. 2002;106:41-50.
14. Chua BH, Chua CC, Diglio CA, Siu BB. Regulation of endothelin-1 mRNA by angiotensin II in rat heart endothelial cells. Biochim Biophys Acta. 1993;1178:201-206.
15. Halim A, Kanayama N, Maradny E, Maehara K, Terao T. Coagulation in vivo microcirculation and in vitro caused by endothelin-1. Thromb Res. 1993;72:203-209.
16. Halim A, Kanayama N, Maradny E, Maehara K, Masahiko H, Terao T. Endothelin-1 increased immunoreactive von Willebrand factor in endo-thelial cells and induced micro thrombosis in rats. Thromb Res. 1994;76: 71-78.
17. Mindukshev IV, Ermolaeva EE, Vivulanets EV, Shabanova EYu, Pet-rishchev NN, Goncharov NV, Jenkins RO, Krivchenko AI. A new method for studying platelets, based upon the low-angle light scattering technique: 2-application of the method in experimental toxicology and clinical pathology. Spectroscopy. 2005;9:5-6.
18. Petnehazy T, Stokes KY, Russell JM, Granger DN. Angiotensin II type-1 receptor antagonism attenuates the inflammatory and thrombogenic responses to hypercholesterolemia in venules. Hypertension. 2005;45: 209-215.
19. Li JS, Touyz RM, Schiffrin EL. Effects of AT1 and AT2 angiotensin receptor antagonists in angiotensin II-infused rats. Hypertension. 1998; 31:487-492.
20. Krebs LT, Kramar EA, Hanesworth JM, Sardinia MF, Ball AE, Wright JW, Harding JW. Characterization of the binding properties and physiological action of divalinal-angiotensin IV, a putative AT4 receptor antagonist. Regul Pept. 1996;67:123-130.
21. Rumbaut RE, Slaff DW, Burns AR. Microvascular thrombosis models in venules and arterioles in vivo. Microcirculation. 2005;12:259-274.
22. Remkova A, Remko M. The role of renin-angiotensin system in pro-thrombotic state in essential hypertension. Physiol Res. 2010;59:13-23.
23. Mogielnicki A, Chabielska E, Pawlak R, Szemraj J, Buczko W. Angio-tensin II enhances thrombosis development in renovascular hypertensive rats. Thromb Haemost. 2005;93:1069-1076.
24. Brown NJ, Agirbasli MA, Williams GH, Litchfield WR, Vaughan DE. Effect of activation and inhibition of the renin-angiotensin system on plasma PAI-1. Hypertension. 1998;32:965-971.
25. Numaguchi Y, Ishii M, Kubota R, Morita Y, Yamamoto K, Matsushita T, Okumura K, Murohara T. Ablation of angiotensin IV receptor attenuates hypofibrinolysis via PAI-1 downregulation and reduces occlusive arterial thrombosis. Arterioscler Thromb Vasc Biol. 2009;29:2102-2108.
26. Crabos M, Bertschin S, Buhler FR, Rogg H, Evequoz D, Eberhard M, Erne P. Identification of AT1 receptors on human platelets and decreased angiotensin II binding in hypertension. J Hypertens. 1993;11(suppl): S230-S231.
27. Thekkumkara TJ, Du J, Dostal DE, Motel TJ, Thomas WG, Baker KM. Stable expression of a functional rat angiotensin II (AT1A) receptor in CHO-K1 cells: rapid desensitization by angiotensin II. Mol Cell Biochem. 1995;146:79-89.
28. Fisslthaler B, Schini-Kerth VB, Fleming I, Busse R. Thrombin receptor expression is increased by angiotensin II in cultured and native vascular smooth muscle cells. Cardiovasc Res. 1998;38:263-271.
29. Ishikawa M, Sekizuka E, Yamaguchi N, Nakadate H, Terao S, Granger DN, Minamitani H. Angiotensin II type 1 receptor signaling contributes to platelet-leukocyte-endothelial cell interactions in the cerebral micro-vasculature. Am J Physiol Heart Circ Physiol. 2007;292:H2306-H2315.
30. Petnehazy T, Stokes KY, Wood KC, Russell J, Granger DN. Role of blood cell-associated AT1 receptors in the microvascular responses to hypercholesterolemia. Arterioscler Thromb Vasc Biol. 2006;26:313-318.
31. Dielis AW, Smid M, Spronk HM, Hamulyak K, Kroon AA, ten Cate H, de Leeuw PW. The prothrombotic paradox of hypertension: role of the renin-angiotensin and kallikrein-kinin systems. Hypertension. 2005;46:1236-1242.
32. Marney AM, Ma J, Luther JM, Ikizler TA, Brown NJ. Endogenous bradykinin contributes to increased plasminogen activator inhibitor 1 antigen following hemodialysis. J Am Soc Nephrol. 2009;20:2246-2252.
33. Marceau F, Hess JF, Bachvarov DR. The B1 receptors for kinins. Pharmacol Rev. 1998;50:357-386.
34. Kerins DM, Hao Q, Vaughan DE. Angiotensin induction of PAI-1 expression in endothelial cells is mediated by the hexapeptide angiotensin IV. J Clin Invest. 1995;96:2515-2520.
35. Skurk T, Lee YM, Hauner H. Angiotensin II and its metabolites stimulate PAI-1 protein release from human adipocytes in primary culture. Hypertension. 2001;37:1336-1340.
36. Vaughan DE, Lazos SA, Tong K. Angiotensin II regulates the expression of plasminogen activator inhibitor-1 in cultured endothelial cells: a potential link between the renin-angiotensin system and thrombosis. J Clin Invest. 1995;95:995-1001.
37. Iwamoto T, Tamaki K, Nakayama M, Okuda S, Fujishima M. Effect of endothelin 1 on fibrinolysis and plasminogen activator inhibitor 1 synthesis in rat mesangial cells. Nephron. 1996;73:273-279.
38. AbdAlla S, Lother H, el Massiery A, Quitterer U. Increased AT(1) receptor heterodimers in preeclampsia mediate enhanced angiotensin II responsiveness. Nat Med. 2001;7:1003-1009.
39. Imai T, Hirata Y, Emori T, Yanagisawa M, Masaki T, Marumo F. Induction of endothelin-1 gene by angiotensin and vasopressin in endo-thelial cells. Hypertension. 1992;19:753-757.
40. Suzuki J, Ogawa M, Muto S, Yamaguchi Y, Itai A, Isobe M. The effects of pharmacological PAI-1 inhibition on thrombus formation and neoin-tima formation after arterial injury. Expert Opin Ther Targets. 2008;12: 783-794.
41. Faure S, Javellaud J, Achard JM, Oudart N. Vasoconstrictive effect of angiotensin IV in isolated rat basilar artery independent of AT1 and AT2 receptors. J Vasc Res. 2006;43:19-26.